It could be argued that drugs reducing insulin levels may reduce cancer risk, and drugs that increase circulating insulin may increase cancer risk, but the effects of metformin in cancer cells seem specific, preventing the boost in glycolytic intermediates, decreasing citric acid cycle intermediates, and depleting the cellular glutathione content [106]. The gene discussed is INS; the disease is cancer.